Comprehensive Stock Analysis Report: Zydus Lifesciences Limited | Scrolls
- Editor
- Oct 1
- 2 min read
by KarNivesh | 01 October, 2025
Overview of Zydus Lifesciences Ltd.
Zydus Lifesciences Ltd. (formerly Cadila Healthcare) has established itself as one of India’s leading pharmaceutical companies and a key player in the global healthcare space. Trading at ₹975 per share, the company reflects strong operational metrics, attractive valuations, and sustainable growth prospects. With a consolidated revenue of ₹23,608 crores in FY2025, Zydus stands as the 5th largest pharmaceutical company in India, supported by a diversified portfolio that includes formulations, APIs, biosimilars, vaccines, and consumer wellness products.
Business and Leadership
The company’s strength lies in its wide-ranging business segments. Formulations dominate, accounting for 70% of revenues, while APIs contribute 20%, followed by consumer wellness at 7%, and others—including vaccines and biologics—at 3%. Zydus maintains a balanced geographic spread, with India contributing 45% of revenues, the USA 30%, Europe 12%, emerging markets 8%, and other regions 5%. Leadership under Chairman Pankaj R. Patel and Managing Director Dr. Sharvil Patel has been instrumental in driving innovation, regulatory compliance, and global expansion.
Key Developments and Achievements
Zydus Lifesciences has recorded several recent milestones:
USFDA Approvals: It secured approval for Sacubitril/Valsartan tablets, which have annual U.S. sales of $5.48 billion (₹45,484 crores).
Strategic Collaborations: The company partnered with Agenus Inc. in a biologics manufacturing deal valued at $141 million (₹1,170 crores).
Pipeline Growth: Significant progress has been made in drug development, including candidates for malaria (ZY19489) and neurological disorders (ZYIL-1).
Manufacturing Excellence: Its Ahmedabad plant received a “zero observation” report from the USFDA, showcasing top-tier compliance.
Industry and Macroeconomic Context
The Indian pharmaceutical industry, valued at $58 billion (₹4.81 lakh crores) in 2025, is projected to grow to $120–130 billion (₹9.96–10.79 lakh crores) by 2030. Government initiatives like the Production Linked Incentive (PLI) Scheme with ₹15,000 crores budget for APIs, 100% FDI in greenfield projects, and ₹3,000 crores allocated for bulk drug parks are fueling growth. India already supplies 20% of the world’s generic medicines, has over 650 FDA-approved plants, and reported pharmaceutical exports of $30.5 billion (₹2.53 lakh crores) in FY2025.
Competitive Landscape
Zydus trades at a P/E ratio of 21.48x, positioning it competitively against peers like Sun Pharma (33.4x), Cipla (23.3x), Mankind Pharma (56.6x), and Dr. Reddy’s (19.0x). Its integrated operations, strong global presence, and significant R&D spending (9.5% of revenue) strengthen its market position. Key products like Lipaglyn® (Saroglitazar), ZyCoV-D (the world’s first DNA COVID-19 vaccine), and a rich biosimilars pipeline with 30 compounds highlight Zydus’ innovation-led strategy.
Governance and Financial Strength
The company upholds strong corporate governance practices, with balanced board oversight and a recent CFO appointment (September 2025). Promoters hold 75% of shares, reinforcing confidence in its long-term growth, while institutional participation enhances market credibility.
Conclusion
Zydus Lifesciences is a robust, innovation-driven pharmaceutical leader with a diversified portfolio and resilient business model. Supported by India’s favorable pharma ecosystem, global opportunities, and its own R&D-focused approach, the company is well-positioned for sustainable growth. With its strong domestic presence, expanding global footprint, and competitive valuation, Zydus Lifesciences continues to stand out as a promising investment in India’s healthcare story.
Comments